MedTrace Logo

Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing

NCT02127684 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-07-30

No results posted yet for this study

Summary

The investigators would like to investigate the efficacy of more frequent treatment with Lucentis for subjects with persistent diabetic macular edema despite standard dosing regimen.

Conditions

  • Persistent Diabetic Macular Edema

Interventions

DRUG

ranibizumab

ranibizumab 0.3mg intravitreally monthly

DRUG

ranibizumab

ranibizumab given every 2 weeks for 8 weeks then monthly as needed

Sponsors & Collaborators

  • Maturi, Raj K., M.D., P.C.

    lead INDIV

Principal Investigators

  • Raj K Maturi, MD · Raj K. maturi MD PC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2015-08-31
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02127684 on ClinicalTrials.gov